Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 71Pituitary Neoplasms 47Thyroid Cancer, Papillary 28Multiple Endocrine Neoplasia Type 1 21Carcinoma, Neuroendocrine 21Pheochromocytoma 18Paraganglioma 14Thyroid Neoplasms 13Carcinoid Tumor 13Neoplasm Metastasis 12Differentiated Thyroid Cancer 12Adrenocortical Carcinoma 11Neoplasms 10Thyroid Carcinoma, Anaplastic 9Pancreatic Neoplasms 8Insulinoma 8Adrenal Gland Neoplasms 8Pituitary Diseases 6Lung Neoplasms 6Hyperaldosteronism 6Gastro-enteropancreatic neuroendocrine tumor 6Acromegaly 6Stomach Neoplasms 5Prostatic Neoplasms 5Prolactinoma 5Head and Neck Neoplasms 5Carcinoma, Hepatocellular 5Breast Neoplasms 5Adrenocortical Adenoma 5Adenoma, Islet Cell 5

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Metatropic dwarfism × Endocrine × Clear all
NCT03629847 2018-08-14

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

King Faisal Specialist Hospital & Research Center

Phase 1/2 Unknown
30 enrolled
EndocrineNET

Metatropic dwarfism, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡